Naim Alkhouri

1 week ago | ajmc.com | Kyle Munz |Naim Alkhouri

Over the past decade, the treatment landscape for metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) has undergone significant transformation, explained Naim Alkhouri, MD, FAASLD, DABOM, chief medical officer, chief of transplant hepatology, and director of the Steatotic Liver Program at Arizona Liver Health.

Nov 27, 2024 | healio.com | Kate Burba |Naim Alkhouri |Monica Stonehill

You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Agile 3+ correctly identified more patients at high risk for MASH (55% vs. 33%). FAST misclassified fewer patients as having low risk MASH among those with stage 2 and 3 fibrosis.